Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document cipargamin - PfATP4 inhibitor Company overview Financial review Conclusions NCT04675931 KARISMA (CKAE609B12201) Malaria severe Phase 2 Indication Phase Patients 252 Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic Immunology Neuroscience Oncology Other > Global Health Abbreviations Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) at 12 hours [ Time Frame: Day 1 (12 Hours)] Arm 1: experimental, IV KAE609 Dose regimen 1 Arm 2: experimental, IV KAE609 Dose regimen 2 Arm 3: experimental, IV KAE609 Dose regimen 3 Arm 4: active comparator, IV Artesunate Arm 5: Coartem, Standard of care Patients with Malaria, severe 2025 References Publication TBD □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 82

View entire presentation